N Staplin, R Haynes, PK Judge, C Wanner, JB Green, J Emberson, D Preiss, KJ Mayne, SYA Ng, E Sammons, et al. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. The Lancet Diabetes & Endocrinology. 2024. 12. 1. 39-50
PK Judge, N Staplin, KJ Mayne, C Wanner, JB Green, SJ Hauske, JR Emberson, D Preiss, SYA Ng, AJ Roddick, et al. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. The Lancet Diabetes & Endocrinology. 2024. 12. 1. 51-60
Naomi Matsumoto, Chigusa Higuchi, Chikara Miyaji, Toshiharu Mitsuhashi, Hideharu Hagiya, Soshi Takao, Takashi Yorifuji. Review of a Series of Surveys on Adverse Reactions to the COVID-19 mRNA-1273 Vaccine at Okayama University. Acta medica Okayama. 2023. 77. 6. 567-575
Initial Two Doses of COVID-19 Vaccine mRNA-1273 for an Individual Previously Vaccinated with Two Doses of an Inactivated Vaccine CoronaVac That Has Not Been Approved in Japan. Acta medica Okayama. 2023. 77. 1. 105-109
Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023. 388. 2. 117-127